Juno Therapeutics Appoints Sunil Agarwal President of R&D

Xconomy Seattle — 

Sunil Agarwal has been appointed president of research and development for Seattle-based cancer immunotherapy company Juno Therapeutics (NASDAQ: JUNO), which has fallen behind its rivals in the race to produce the first commercial T cell therapy known as CAR-T. Before joining Juno, Agarwal was chief medical officer of Novato, CA-based Ultragenyx Pharmaceutical (NASDAQ: RARE). His experience also includes several senior leadership positions at Genentech.